Can incontinence be cured? A systematic review of cure rates

Table 3 Cure rates^a in studies for female and male patients with mixed urinary incontinence

Follow-up	3 m	6 m	12 m	18 m	2 y	5 y
Treatment – WOMEN
TVT		NR
Retropubic TVT		89.7%	86.1%	80.1	77.4%
SPARC	83.1% W	82.3% W	84.4% W
Sling	94.1%	81.3%; 89.8%	63.7%; 90.2%	52.8%	50.5%; 83.7%;
PFMT – supervised	5%				NR	8 y: NR
PFMT + neuromodulation^b	93%
PFMT + lifestyle advice	25%	28%
Vaginal cone therapy	9%
PFMT – supervised + delivery			17%
Lifestyle advice (supervised)	8%
Solifenacin			52%
Duloxetine	NR
Treatment – MEN
Solifenacin	26.5%
PFMT – supervised	44%; 46.3%	47%; 66.7%	24%; 35%; 60%; 83.4%
PFMT – unsupervised	40%	50%	64%
Lifestyle advice – unsupervised			23%; 38%

^aCure defined as ‘cure’, ‘objective cure’, ‘success (dry)’ or complete continence
^bSuccess, defined as ‘An absence of incontinent episodes (dry) and an OAB-V8 score < 8, indicating no OAB’
NR not reported; PFMT pelvic floor muscle training; TVT tension-free vaginal tape; W with containment products

ISSN: 1741-7015